# ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

> **NCT03338816** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 94 (actual)

## Conditions studied

- Acute Hepatic Porphyria
- Acute Intermittent Porphyria
- Porphyria, Acute Intermittent
- Acute Porphyria
- Hereditary Coproporphyria (HCP)
- Variegate Porphyria (VP)
- ALA Dehydratase Deficient Porphyria (ADP)

## Interventions

- **DRUG:** Givosiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03338816
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2019-01-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338816, "ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03338816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*